Blockers of IL1RI and IL-1β have been used in the treatment of rheumatoid arthritis, breast cancer, and other diseases, but there is still a lack of research and application in ocular surface inflammatory diseases [42,43,44]. This evidence concerns the gene IL1B and breast carcinoma.